Literature DB >> 29313889

Inventing new therapies without reinventing the wheel: the power of drug repurposing.

Andreas Papapetropoulos1,2, Csaba Szabo3.   

Abstract

LINKED ARTICLES: This article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc.
© 2018 The British Pharmacological Society.

Mesh：

Year:  2018        PMID： 29313889      PMCID： PMC5758397          DOI： 10.1111/bph.14081

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  28 in total

Review 1.  Diagnosing the decline in pharmaceutical R&D efficiency.

Authors:  Jack W Scannell; Alex Blanckley; Helen Boldon; Brian Warrington
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

Review 2.  Identification of drug candidates and repurposing opportunities through compound-target interaction networks.

Authors:  Anna Cichonska; Juho Rousu; Tero Aittokallio
Journal:  Expert Opin Drug Discov       Date:  2015-10-01       Impact factor: 6.098

3.  Glycogen phosphorylase inhibition improves beta cell function.

Authors:  Lilla Nagy; Judit Márton; András Vida; Gréta Kis; Éva Bokor; Sándor Kun; Mónika Gönczi; Tibor Docsa; Attila Tóth; Miklós Antal; Pál Gergely; Balázs Csóka; Pal Pacher; László Somsák; Péter Bai
Journal:  Br J Pharmacol       Date:  2017-06-18       Impact factor: 8.739

Review 4.  Drug repurposing: translational pharmacology, chemistry, computers and the clinic.

Authors:  Naiem T Issa; Stephen W Byers; Sivanesan Dakshanamurthy
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

5.  Drug repurposing and the prior art patents of competitors.

Authors:  Christian Sternitzke
Journal:  Drug Discov Today       Date:  2014-09-28       Impact factor: 7.851

Review 6.  Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.

Authors:  Nathan A Berger; Valerie C Besson; A Hamid Boulares; Alexander Bürkle; Alberto Chiarugi; Robert S Clark; Nicola J Curtin; Salvatore Cuzzocrea; Ted M Dawson; Valina L Dawson; György Haskó; Lucas Liaudet; Flavio Moroni; Pál Pacher; Peter Radermacher; Andrew L Salzman; Solomon H Snyder; Francisco Garcia Soriano; Robert P Strosznajder; Balázs Sümegi; Raymond A Swanson; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-26       Impact factor: 8.739

Review 7.  Drug repurposing in oncology--patient and health systems opportunities.

Authors:  Francesco Bertolini; Vikas P Sukhatme; Gauthier Bouche
Journal:  Nat Rev Clin Oncol       Date:  2015-10-20       Impact factor: 66.675

8.  Dexpramipexole improves bioenergetics and outcome in experimental stroke.

Authors:  Mirko Muzzi; Elisabetta Gerace; Daniela Buonvicino; Elisabetta Coppi; Francesco Resta; Laura Formentini; Riccardo Zecchi; Laura Tigli; Daniele Guasti; Martina Ferri; Emidio Camaioni; Alessio Masi; Domenico E Pellegrini-Giampietro; Guido Mannaioni; Daniele Bani; Anna M Pugliese; Alberto Chiarugi
Journal:  Br J Pharmacol       Date:  2017-05-12       Impact factor: 8.739

Review 9.  Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines.

Authors:  Guangxu Jin; Stephen T C Wong
Journal:  Drug Discov Today       Date:  2013-11-14       Impact factor: 7.851

Review 10.  Drug repurposing screens and synergistic drug-combinations for infectious diseases.

Authors:  Wei Zheng; Wei Sun; Anton Simeonov
Journal:  Br J Pharmacol       Date:  2017-07-09       Impact factor: 8.739
View more
  17 in total

1.  Inventing new therapies without reinventing the wheel: the power of drug repurposing.

Authors:  Andreas Papapetropoulos; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2018-01       Impact factor: 8.739

2.  Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.

Authors:  Henry R O'Donnell; Tia A Tummino; Conner Bardine; Charles S Craik; Brian K Shoichet
Journal:  J Med Chem       Date:  2021-11-23       Impact factor: 7.446

3.  Promethazine exhibits antiparasitic properties in vitro and reduces worm burden, egg production, hepato-, and splenomegaly in a schistosomiasis animal model.

Authors:  Daniel B Roquini; Ramon M Cogo; Ana C Mengarda; Susana F Mazloum; Cristiane S Morais; Rogério P Xavier; Maria C Salvadori; Fernanda S Teixeira; Luiz E Ferreira; Pedro L Pinto; Thiago R Morais; Josué de Moraes
Journal:  Antimicrob Agents Chemother       Date:  2019-09-16       Impact factor: 5.191

Review 4.  Tetracycline repurposing in neurodegeneration: focus on Parkinson's disease.

Authors:  Mariza Bortolanza; Glauce C Nascimento; Sergio B Socias; Diego Ploper; Rosana N Chehín; Rita Raisman-Vozari; Elaine Del-Bel
Journal:  J Neural Transm (Vienna)       Date:  2018-08-14       Impact factor: 3.575

5.  Topological network measures for drug repositioning.

Authors:  Apurva Badkas; Sébastien De Landtsheer; Thomas Sauter
Journal:  Brief Bioinform       Date:  2021-07-20       Impact factor: 11.622

Review 6.  Changing Trends in Computational Drug Repositioning.

Authors:  Jaswanth K Yella; Suryanarayana Yaddanapudi; Yunguan Wang; Anil G Jegga
Journal:  Pharmaceuticals (Basel)       Date:  2018-06-05

Review 7.  Turning liabilities into opportunities: Off-target based drug repurposing in cancer.

Authors:  Vinayak Palve; Yi Liao; Lily L Remsing Rix; Uwe Rix
Journal:  Semin Cancer Biol       Date:  2020-02-07       Impact factor: 15.707

Review 8.  Repurposing Pharmaceuticals Previously Approved by Regulatory Agencies to Medically Counter Injuries Arising Either Early or Late Following Radiation Exposure.

Authors:  Vijay K Singh; Thomas M Seed
Journal:  Front Pharmacol       Date:  2021-05-10       Impact factor: 5.810

9.  Pyrvinium Pamoate Induces Death of Triple-Negative Breast Cancer Stem-Like Cells and Reduces Metastases through Effects on Lipid Anabolism.

Authors:  Rosanna Dattilo; Carla Mottini; Emanuela Camera; Alessia Lamolinara; Noam Auslander; Ginevra Doglioni; Michela Muscolini; Wei Tang; Melanie Planque; Cristiana Ercolani; Simonetta Buglioni; Isabella Manni; Daniela Trisciuoglio; Alessandra Boe; Sveva Grande; Anna Maria Luciani; Manuela Iezzi; Gennaro Ciliberto; Stefan Ambs; Ruggero De Maria; Sarah-Maria Fendt; Eytan Ruppin; Luca Cardone
Journal:  Cancer Res       Date:  2020-07-23       Impact factor: 12.701

10.  Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach.

Authors:  Ikechukwu Achilonu; Emmanuel Amarachi Iwuchukwu; Okechinyere Juliet Achilonu; Manuel Antonio Fernandes; Yasien Sayed
Journal:  J Mol Graph Model       Date:  2020-09-02       Impact factor: 2.518
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.